肽类药物在肿瘤治疗中的研究进展

doi:10.3760/cma.j.issn.1673-422X.2015.01.014

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (1): 52-55.doi: 10.3760/cma.j.issn.1673-422X.2015.01.014

肽类药物在肿瘤治疗中的研究进展

张自强, 杨晓峰, 刘杰昊

030001太原，山西医科大学第一附属医院泌尿外科

收稿日期:2014-06-03 修回日期:2014-07-14 出版日期:2015-01-08 发布日期:2015-01-07
通讯作者: 杨晓峰 E-mail:yxfylq@163.com
基金资助:
国家自然科学基金（81172444）

Advances of peptides in cancer treatment

Zhang Ziqiang, Yang Xiaofeng, Liu Jiehao

Department of Urology Surgery, First Affiliated Hospital of Shanxi Medical University, Taiyuan 030001, China

Received:2014-06-03 Revised:2014-07-14 Online:2015-01-08 Published:2015-01-07
Contact: Yang Xiaofeng E-mail:yxfylq@163.com

摘要/Abstract

摘要： 研究表明肽类药物对肿瘤生长具有抑制作用，在肿瘤治疗方面有巨大潜能。多肽可以作为激素、疫苗、放射性核素及细胞毒药物的载体和抗肿瘤药物在肿瘤的治疗中发挥重要作用。利用多肽的靶向性化疗和靶向性的药物输送技术能使药物高度选择地、有效地聚集在预定目标，正逐渐成为传统化疗方案的一种补充治疗方案。

关键词: 肿瘤, 肽类, 抗肿瘤药, 分子靶向治疗

Abstract: Studies demonstrate that peptides have great potential in cancer therapy and inhibitation of tumor progression. Peptides can be used as hormones, vaccines, carriers of redionuclides and cytotoxic drugs as well as antitumor drugs playing important roles in oncotherapy. Targeting chemotherapy and targeting drug transportation technique can enable the drugs to concentrate expected location selectively and effectively, emerging as an alternative to the conventional chemotherapy.

Key words: Neoplasms, Peptides, Antineoplastic agents, Molecular targeted therapy

张自强, 杨晓峰, 刘杰昊. 肽类药物在肿瘤治疗中的研究进展[J]. 国际肿瘤学杂志, 2015, 42(1): 52-55.

Zhang Ziqiang, Yang Xiaofeng, Liu Jiehao. Advances of peptides in cancer treatment[J]. Journal of International Oncology, 2015, 42(1): 52-55.

参考文献

［1］ Meng L, Yang L, Zhao X, et al. Targeted delivery of chemotherapy agents using a liver cancerspecific aptamer［J］. PLoS One, 2012, 7(4): e33434. ［2］ Zhang XX, Eden HS, Chen X. Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates［J］. J Control Release, 2012, 159(1): 2-13. ［3］ Nicolas G, Giovacchini G, MüllerBrand J, et al. Targeted radiotherapy with radiolabeled somatostatin analogs［J］. Endocrinol Metab Clin North Am, 2011, 40(1): 187-204. ［4］ Putzer D, Gabriel M, Henninger B, et al. Bone metastases in patients with neuroendocrine tumor: 68GaDOTATyr3octreotide PET in comparison to CT and bone scintigraphy［J］. J Nucl Med, 2009, 50(8): 1214-1221. ［5］ Bison SM, Konijnenberg MW, Melis M, et al. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments［J］. Clin Transl Imaging, 2014, 2: 55-66. ［6］ Zaccaro L, Del Gatto A, Pedone C, et al. Peptides for tumour therapy and diagnosis: current status and future directions［J］. Curr Med Chem, 2009, 16(7): 780-795. ［7］ Yan Y, Chen K, Yang M, et al. A new 18Flabeled BBNRGD peptide heterodimer with a symmetric linker for prostate cancer imaging［J］. Amino Acids, 2011, 41(2): 439-447. ［8］ Tweedle MF. Peptidetargeted diagnostics and radiotherapeutics［J］. Acc Chem Res, 2009, 42(7): 958-968. ［9］ Wild D, Fani M, Behe M, et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible［J］. J Nucl Med, 2011, 52(9): 1412-1417. ［10］ Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV16 oncoproteins for vulvar intraepithelial neoplasia［J］. N Engl J Med, 2009, 361(19): 1838-1847. ［11］ Bolonaki I, Kotsakis A, Papadimitraki E, et al. Vaccination of patients with advanced nonsmallcell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide［J］. J Clin Oncol, 2007, 25(19): 2727-2734. ［12］ Bedke J, Stenzl A. IMA901: a peptide vaccine in renal cell carcinoma［J］. Expert Opin Investig Drugs, 2013, 22(10): 13291336. ［13］ Zhang Z, Chen X, Chang X, et al. Vaccination with embryonic stem cells generates effective antitumor immunity against ovarian cancer［J］. Int J Mol Med, 2013, 31(1): 147-153. ［14］ Wiedermann U, Davis AB, Zielinski CC. Vaccination for the prevention and treatment of breast cancer with special focus on Her2/neu peptide vaccines［J］. Breast Cancer Res Treat, 2013, 138(1): 1-12. ［15］ Kimura T, McKolanis JR, Dzubinski LA, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study［J］. Cancer Prev Res (Phila), 2013, 6(1): 18-26. ［16］ Kelly RJ, Giaccone G. Lung cancer vaccines［J］. Cancer J, 2011, 17(5): 302-308. ［17］ Okuno K, Sugiura F, Itoh K, et al. Recent advances in active specific cancer vaccine treatment for colorectal cancer［J］. Curr Pharm Biotechnol, 2012, 13(8): 1439-1445. ［18］ Weber JS, Vogelzang NJ, Ernstoff MS, et al. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostatespecific membrane antigen in patients with advanced solid tumors［J］. J Immunother, 2011, 34(7): 556-567. ［19］ Akhtar NH, Pail O, Saran A, et al. Prostatespecific membrane antigenbased therapeutics［J］. Adv Urol, 2012, 2012: 973820. ［20］ Toubaji A, Achtar M, Provenzano M, et al. Pilot study of mutant ras peptidebased vaccine as an adjuvant treatment in pancreatic and colorectal cancers［J］. Cancer Immunol Immunother, 2008, 57(9): 1413-1420. ［21］ Markowicz S, Nowecki ZI, Rutkowski P, et al. Adjuvant vaccination with melanoma antigenpulsed dendritic cells in stage Ⅲ melanoma patients［J］. Med Oncol, 2012, 29(4): 2966-2977. ［22］ Chen K, Chen X. Integrin targeted delivery of chemotherapeutics［J］. Theranostics, 2011, 1: 189-200. ［23］ Schally AV, Engel JB, Emons G, et al. Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors［J］. Curr Drug Deliv, 2011, 8(1): 1125. ［24］ Laakkonen P, Vuorinen K. Homing peptides as targeted delivery vehicles［J］. Integr Biol (Camb), 2010, 2(7-8): 326-337. ［25］ Li ZJ, Cho CH. Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery［J］. J Transl Med, 2012, 10 Suppl 1: S1. ［26］ Sotomayor S, MunozMoreno L, Carmena MJ, et al. Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN215) and a bombesin antagonist (RC3095) ［J］. Int J Cancer, 2010, 127(8): 1813-1822. ［27］ Rosca EV, Koskimaki JE, Rivera CG, et al. Antiangiogenic peptides for cancer therapeutics［J］. Curr Pharm Biotechnol, 2011, 12(8): 1101-1116. ［28］ Cardinale D, Guaitoli G, Tondi D, et al. Proteinprotein interfacebinding peptides inhibit the cancer therapy target human thymidylate synthase［J］. Proc Natl Acad Sci USA, 2011, 108(34): E542-549.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

肽类药物在肿瘤治疗中的研究进展

Advances of peptides in cancer treatment

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价